Sharp Launches Clinventory IMS
Sharp, part of UDG Healthcare plc, has launched a new Inventory Management System (IMS) to support clinical trial sponsors in managing inventory and supplies.
The new system—named Clinventory—has been designed to provide full visibility of stock levels at investigator sites and tracking product through the supply chain.
Using the Clinventory IMS will also create efficiencies for trial sponsors by aiming to improve the drug management process by leveraging automation to increase reliability.
Sascha Sonnenberg, Global Head of Business Development at Sharp Clinical said “Clinventory has been designed specifically with those smaller-volume, early stage or open label clinical trials in mind, where a larger, more expensive inventory system might offer an array of functionality that is surplus to needs.”
Read the full release and learn more, here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
